Abstract
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels play important roles both in the control of heart rate and neuronal excitability. HCN channels open on hyperpolarization voltage, permeate to potassium and sodium, and generate an inward current, which is modulated by intracellular cAMP. HCN channels have been reported to involve in various human diseases, including heart failure, pain and epilepsy with datas from mutagenesis, transgenic mice and pharmacological studies. As a result, HCN channels may offer excellent drug development opportunities for novel analgestic, bradycardic and anticonvulsant drugs. Ivabradine is the first HCN channel inhibitor being clinically approved in 2005 for the treatment of chronic stable angina pectoris and heart failure. This review will summarize the structure and function of HCN channels. Further, we will discuss recent advances concerning the identification and action mechanism of reported HCN channel inhibitors.
Keywords: Arrhythmia, channel inhibitors, epilepsy, HCN channels, heart failure, ivabradine, pain
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:HCN Channel as Therapeutic Targets for Heart Failure and Pain
Volume: 16 Issue: 16
Author(s): Ying Cao, Jianxin Pang and Pingzheng Zhou
Affiliation:
Keywords: Arrhythmia, channel inhibitors, epilepsy, HCN channels, heart failure, ivabradine, pain
Abstract: Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels play important roles both in the control of heart rate and neuronal excitability. HCN channels open on hyperpolarization voltage, permeate to potassium and sodium, and generate an inward current, which is modulated by intracellular cAMP. HCN channels have been reported to involve in various human diseases, including heart failure, pain and epilepsy with datas from mutagenesis, transgenic mice and pharmacological studies. As a result, HCN channels may offer excellent drug development opportunities for novel analgestic, bradycardic and anticonvulsant drugs. Ivabradine is the first HCN channel inhibitor being clinically approved in 2005 for the treatment of chronic stable angina pectoris and heart failure. This review will summarize the structure and function of HCN channels. Further, we will discuss recent advances concerning the identification and action mechanism of reported HCN channel inhibitors.
Export Options
About this article
Cite this article as:
Cao Ying, Pang Jianxin and Zhou Pingzheng, HCN Channel as Therapeutic Targets for Heart Failure and Pain, Current Topics in Medicinal Chemistry 2016; 16 (16) . https://dx.doi.org/10.2174/1568026616666151215104058
DOI https://dx.doi.org/10.2174/1568026616666151215104058 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peripheral and Central Glutamate Dyshomeostasis in Neurodegenerative Disorders
Current Neuropharmacology Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Molecular Docking Studies and Inhibition Properties of Some Antineoplastic Agents against Paraoxonase-I
Anti-Cancer Agents in Medicinal Chemistry Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Medication-precipitated Seizure in Psychiatric Patients: Typical vs. Atypical Antipsychotics
Current Psychopharmacology Editorial [Hot Topic: Anticonvulsant Agents (Guest Editor: Barbara Malawska)]
Current Topics in Medicinal Chemistry Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Infectious Disorders - Drug Targets Histamine H3 Receptor: A Potential Drug Target for the Treatment of Central Nervous System Disorders
Current Drug Targets - CNS & Neurological Disorders Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Damaged Proteins Bearing L-Isoaspartyl Residues and Aging: A Dynamic Equilibrium Between Generation of Isomerized Forms and Repair by PIMT
Current Aging Science G Protein-Activated Inwardly Rectifying Potassium Channels as Potential Therapeutic Targets
Current Pharmaceutical Design New Therapeutic Strategies in Perinatal Stroke
Current Drug Targets - CNS & Neurological Disorders Triggers of Cell Death in the Developing Brain
Current Pediatric Reviews Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research Management of Antiepileptic Treatment After Epilepsy Surgery - Practices and Problems
Current Pharmaceutical Design Assessment of Possible Drug Interactions in Patients with Psoriasis and Associated Comorbid Medical Conditions: An Observational Study
Reviews on Recent Clinical Trials Anticonvulsants – Antidepressants Pharmacokinetic Drug Interactions: The Role of the CYP450 System in Psychopharmacology
Current Drug Metabolism Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology